- Tivozanib for RCC
- Genitourinary Oncology: A Peek Over the ...
- Immunotherapy of Renal Cell Carcinoma
- Targeted Therapies for Renal Cell Carcinoma
- Genetics and Heterogeneity
- Genetic Predisposition to Kidney Cancers
- Personalized Medicines for Kidney Cancers
- Drugs in the Pipeline
- Resistance to Therapy Among Kidney Cancers
- Targeted Therapy
- The Role of Neoadjuvant Tx
- Sx Options – Ablative Techniques
- Sx Options – Lymph Node
- Sx Options – Cytoreductive Nephrectomy
- TKIs - First-Line Therapy
- TKIs – Second-Line Therapy
- Biomarkers in RCC
- The MET Pathway
- Checkpoint Inhibitors
Renal Cell Carcinoma News
Biomarkers May Predict Patient Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma
More Renal Cell Carcinoma Information
Both the chemotherapy regimen selected and therapeutic dose intensity used in treatment factor into the calculation of neutropenia risk.
Traditional genetic testing historically included the sequential analysis of single and generally well-described genes involved in heritable cancers.
Some data suggest that psychotherapy may benefit patients with cancer, but higher-quality research is needed.
The effect of polypharmacy and noncancer mortality on patient survival and other outcomes in cancer varies by study.
Though it is clear that cancer is associated with an extreme financial burden, the extent of the burden varies widely.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|